Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension
This study found that early selexipag addition to ERA plus PDE5i was associated with a reduction in risk of hospitalization and disease progression. These findings suggest that delays in selexipag initiation likely contribute to suboptimal patient and health system outcomes.
Authors
- Wenze Tang (ORCID: https://orcid.org/0000-0002-0491-8842)
- Charles D. Burger (ORCID: https://orcid.org/0000-0002-4815-3669)
- Sumeet Panjabi (ORCID: https://orcid.org/0000-0002-5093-8510)
- Yuen Tsang
Institutions
- Johnson & Johnson (United States) (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.34691
- Citations
- 3
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Janssen Scientific Affairs
- Actelion Pharmaceuticals